Background: Pigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus (PHID) is one of the rare H syndrome diseases mainly characterized by hyperpigmentation, hypertrichosis, sensorineural hearing loss, cardiac complications, developmental delay, and diabetes mellitus (DM). Mutations in the coding regions of the SLC29A3 gene that encodes for an equilibrative nucleoside transporter (ENT3) have been reported to cause the phenotypic spectrum of the H syndrome. Disease-causing mutations in the untranslated regions (UTRs) of the SLC29A3 gene have not been previously described in the literature. The aim of the study is to describe and assess the pathogenicity of a novel 3'UTR mutation in the SLC29A3 gene associated with the PHID phenotype in two Turkish patients.

Methods: The mutation was identified by a targeted gene approach. To understand the pathogenicity of this 3'UTR mutation, RNA and protein expression studies were performed by using the quantitative real-time polymerase chain reaction method and western blotting, respectively, using fibroblasts cultured from the patients' skin biopsies.

Results: SLC29A3 and ENT3 expression levels were both decreased in the patients compared to controls matched for passage numbers, RNA, and protein extraction methods.

Conclusions: A novel 3'UTR mutation in the SLC29A3 gene is associated with the PHID syndrome, highlighting a potentially new pathological mechanism for this disease. The involvement of the 3'UTR has not been previously established in any of the H syndrome disease cluster or in any complex syndrome of DM.

Download full-text PDF

Source
http://dx.doi.org/10.1111/pedi.12839DOI Listing

Publication Analysis

Top Keywords

slc29a3 gene
20
mutation slc29a3
12
gene associated
12
diabetes mellitus
12
3'utr mutation
12
pigmentary hypertrichosis
8
hypertrichosis non-autoimmune
8
non-autoimmune insulin-dependent
8
insulin-dependent diabetes
8
novel 3'utr
8

Similar Publications

Article Synopsis
  • The study investigates the role of solute carrier family transporters (SLCs) in the placenta, linking their dysregulation to pregnancy disorders like preeclampsia (PE) and intrauterine growth restriction (IUGR).
  • Researchers conducted a meta-analysis of public data and verified findings through qPCR, focusing on differentially expressed SLCs in PE and IUGR samples.
  • The results showed significant downregulation of specific SLCs (SLC6A8, SLC16A10, SLC25A3, SLC29A3) in affected placental samples, suggesting their potential role in the pathogenesis of these pregnancy complications.
View Article and Find Full Text PDF
Article Synopsis
  • - Gemcitabine is a cancer drug effective against tumors like pancreatic and lung cancers, but its effectiveness has been declining due to genetic instability, prompting research into gene polymorphisms that may affect drug metabolism.
  • - This study analyzed gene polymorphism frequencies related to gemcitabine metabolism in healthy and lung cancer patients from Southern India, utilizing real-time polymerase chain reaction to genotype 184 healthy individuals and 123 lung cancer patients.
  • - Results showed significant differences in allele frequencies for specific SNPs between the South Indian population and the 1000 Genomes Project, with one SNP showing a potential protective effect against lung cancer.
View Article and Find Full Text PDF

Pathogenic Variants Resulting in Dural Based Fibroinflammatory Mass Lesions and H Syndrome Treated With Cobimetinib: A Case Report.

Neurol Genet

December 2024

From the Department of Neurology (S.A.B., A.J.A., G.F.K., N.K., W.O.T.); Division of Hematology (J.P.A., J.C.V., R.G.); Division of Hematopathology (K.R.); Division of Neuroradiology (P.M.); Department of Clinical Genomics (Q.K.G.T., L.N.V.); Division of General Internal Medicine (K.L.S.); Department of Dermatology (S.S.D., H.S.M.); Division of Endocrinology (C.J.D.-P.), Diabetes, Nutrition; and Center for Multiple Sclerosis and Autoimmune Neurology at Mayo Clinic (W.O.T.), Rochester, MN.

Objectives: Pathogenic variants are known to cause autosomal recessive disease with a spectrum of systemic involvement. We sought to expand on the spectrum of variants and describe potential treatment.

Methods: We describe a case of newly diagnosed -related disorder, also known as H syndrome or familial histiocytosis, associated with CNS inflammatory pseudotumor and spinal cord compression.

View Article and Find Full Text PDF

H syndrome is a rare autosomal recessive genodermatosis that falls under the histiocytosis-lymphadenopathy plus syndrome. The term "H syndrome" includes manifestations such as hyperpigmentation, hypertrichosis, hepatosplenomegaly, heart anomalies, hearing loss, hypogonadism, low height, and occasionally hyperglycemia. The syndrome is associated with mutations in the SLC29A3 gene, which encodes the human equilibrative transporter 3 present in endosomes, lysosomes, and mitochondria.

View Article and Find Full Text PDF

Rheumatological manifestations of H syndrome.

Reumatologia

September 2024

Rheumatology Department B, Al Ayachi Hospital, Ibn Sina Hospital Centre, Mohammed V University, Rabat, Morocco.

Article Synopsis
  • H syndrome is a rare genetic condition characterized by skin changes (like hyperpigmentation and excessive hair growth) and affects multiple body systems due to a specific gene mutation.
  • A case study of a 24-year-old Moroccan male with insulin-dependent diabetes shows various symptoms, including skin issues and musculoskeletal problems like foot abnormalities and joint contractures.
  • The report emphasizes the serious rheumatological impacts of H syndrome and discusses potential treatments to help improve these musculoskeletal issues.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!